Charles Sammons Cancer Center, Baylor University Medical Center, US Oncology Network, Dallas, TX 75246, USA.
Ontada, Boston, MA 02110, USA.
Future Oncol. 2023 Aug;19(26):1785-1800. doi: 10.2217/fon-2023-0170. Epub 2023 Sep 4.
Pathologic response has been shown to be a promising surrogate for survival in non-small-cell lung cancer. We examined the real-world relationship between these end points in patients with resectable stage IB-IIIA non-small-cell lung cancer receiving neoadjuvant chemotherapy/chemoradiotherapy (CT/CRT). Electronic health records/medical charts were analyzed. Overall and event-free survival (OS/EFS) were assessed by Kaplan-Meier stratified by pathologic response. Associations between the end points were assessed by Cox analyses. A total of 425 patients were selected for the study; 147 and 278 received CT and CRT, respectively. Pathologic complete response (pCR) was associated with longer OS (adjusted HR = 0.50; 95% CI: 0.29-0.85) and EFS (adjusted HR = 0.44; 95% CI: 0.28-0.68) versus no pCR, and EFS was associated with OS (HR = 0.51, 95% CI: 0.38, 0.69). In patients receiving neoadjuvant CT/CRT, pCR and EFS were associated with improved survival in this real-world dataset.
病理缓解已被证明是预测非小细胞肺癌生存的有前途的替代指标。我们研究了接受新辅助化疗/放化疗（CT/CRT）的可切除 IB-IIIA 期非小细胞肺癌患者的这些终点之间的真实世界关系。分析了电子健康记录/病历。通过 Kaplan-Meier 分层按病理缓解评估总生存期（OS）和无事件生存期（EFS）。通过 Cox 分析评估终点之间的关联。共选择了 425 名患者进行研究；分别有 147 名和 278 名患者接受了 CT 和 CRT。与无 pCR 相比，病理完全缓解（pCR）与更长的 OS（调整后的 HR=0.50；95%CI：0.29-0.85）和 EFS（调整后的 HR=0.44；95%CI：0.28-0.68）相关，而 EFS 与 OS 相关（HR=0.51，95%CI：0.38，0.69）。在接受新辅助 CT/CRT 的患者中，pCR 和 EFS 与该真实世界数据集中的生存改善相关。
